HCPLive
American Diabetes Association 74th Scientific Sessions

American Diabetes Association 74th Scientific Sessions | ADA 2014

The American Diabetes Association's 74th Scientific Sessions, billed as "the world's foremost meeting on diabetes," will feature more than 14,000 top scientists, physicians, and other health care professionals sharing "cutting-edge research, treatment recommendations and advances toward a cure for diabetes."

Conference Coverages

Transplantation of Human Islet Cells Safe and Effective in Type 1 Diabetes
Transplantation of Human Islet Cells Safe and Effective in Type 1 Diabetes
Phase III trial shows that transplanted purified human pancreatic islets safely restored sustained near-normoglycemia and provided protection from severe hypoglycemia in patients with long-standing type 1 diabetes and iatrogenic hypoglycemia.
Swedish Study Indicates LDL Cholesterol Not a Good Marker of Cardiovascular Risk in Type 1 Diabetes
Researchers find that the ratio of total cholesterol to HDL is a significant predictor for CVD in type 1 diabetes patients who are not using lipid-lowering drugs, and that the ratio of total cholesterol to HDL is a more reliable marker for risk when considering primary prevention.
Inhibition of SGLT2 in Pancreatic Alpha Cells Drives Glucagon Gene Expression
Researchers have identified a previously unrecognized mechanism for SGLT2 inhibitors in the regulation of glucagon and gluconeogenic gene expression.
Depressive Symptoms Predict Increased Mortality Rates in Both Men and Women with Type 1 Diabetes
Patients with type 1 diabetes who had more depressive symptoms measured at baseline and over time appear to be at an increased risk of mortality, even after allowing for likely mediators.
Combination Treatment with SGLT2 Inhibitor Dapagliflozin Is Effective in Patients with Type 2 Diabetes
Patients with type 2 diabetes and inadequate glycemic control treated with dapagliflozin plus metformin and sulfonylurea experienced sustained improvements in HbA1c, fasting plasma glucose, weight loss, and systolic blood pressure over 52 weeks.
Evaluating the Long-term Efficacy and Safety of SGLT2 Inhibitor Canagliflozin in Older Patients with Type 2 Diabetes
Patients between the ages of 55 and 80 with type 2 diabetes treated with canagliflozin for more than 100 weeks experienced significant reductions in HbA1C, fasting plasma glucose, bodyweight, and systolic blood pressure.
Empagliflozin Monotherapy Trial Extension Highlights Advantages of SGLT2 Inhibitors for Treatment of Type 2 Diabetes
Study results show long-term treatment with empagliflozin was well tolerated and associated with reductions in HbA1c, bodyweight, and systolic blood pressure compared with placebo and sitagliptin.
Novel, Incretin-based Oral Combination Therapy: A Possible Replacement for Insulin as First-line Therapy in Newly Diagnosed Type 2 Diabetes Patients
Study results presented at ADA 2014 show combination treatment with metformin plus linagliptin delivered consistent HbA1c reductions across different subgroups of patients newly diagnosed with type 2 diabetes, with decreased risk of hypoglycemia.
Novel Orally Available GLP-1 Agonist Lowers HbA1c in Patients with Type 2 Diabetes
Study results show that an alternative to currently-marketed injectable agents retains the efficacy of GLP-1 mimetics, while reducing gastrointestinal adverse events and providing the convenience of oral dosing.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$